Study Summary
This trial is testing the safety and effectiveness of a new drug, zilovertamab vedotin, for people with certain types of lymphoma who have not responded well to other treatments.
- Richter Transformation Lymphoma
- Chronic Lymphocytic Leukemia
- Mantle Cell Lymphoma
- Follicular Lymphoma
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
10 Primary · 9 Secondary · Reporting Duration: Up to approximately 57 months
Trial Safety
Phase-Based Safety
Awards & Highlights
Trial Design
8 Treatment Groups
Zilovertamab vedotin 2.5 mg/kg
1 of 8
Zilovertamab vedotin 2.0 mg/kg
1 of 8
Cohort A
1 of 8
Cohort B
1 of 8
Cohort C
1 of 8
Cohort D
1 of 8
Cohort E
1 of 8
Cohort F
1 of 8
Experimental Treatment
275 Total Participants · 8 Treatment Groups
Primary Treatment: Zilovertamab vedotin · No Placebo Group · Phase 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 0 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
What potential perils could arise from ingesting Zilovertamab vedotin?
"Assessment of the safety profile for Zilovertamab vedotin scored a 2 on our team's scale due to being in Phase 2, where there is some evidence backing its security but none attesting to efficacy." - Anonymous Online Contributor
How many volunteers are currently engaged in this research study?
"Affirmative, clinicaltrials.gov verifies that this medical trial is currently recruiting patients. Initially posted on July 21st 2022 and most recently edited on November 24th 2022, 275 participants are needed from 4 different sites." - Anonymous Online Contributor
How many locations have been approved to conduct this experiment?
"At this time, 4 clinics in Decatur, Saint Matthews, Spokane and other cities are enrolling patients for the trial. To reduce travel burdens associated with participation it is important to pick a clinic that is most proximal to you." - Anonymous Online Contributor
What is the ultimate aim of this research endeavor?
"This clinical trial will assess efficacy over almost 5 years and the primary endpoint is Percentage of Participants Discontinuing from Study Therapy Due to Adverse Events (cohort C and D). Additionally, Duration of Response per Lugano Response Criteria as Assessed by BICR (cohorts A, B, D (FL), and E) as well as Duration of Response per iwCLL Criteria as Assessed by Investigator (cohorts D [CLL] and F) will be evaluated. Finally, a measure for Percentage of Participants Discontinuing from Study Therapy Due to AE's in cohorts A-" - Anonymous Online Contributor
Is there an opportunity to join this experiment currently?
"Affirmative. Clinicaltrials.gov indicates that, as of November 24th 2022, this research is actively seeking participants; with an initial posting date of July 21st 2022 and a goal to recruit 275 patients across 4 sites." - Anonymous Online Contributor